ACLXHIGH SIGNALFINANCIAL10-K

ACLX experienced a substantial decline in revenue alongside meaningfully higher operating losses, indicating significant deterioration in the company's financial performance.

The sharp revenue contraction combined with substantially expanded operating losses suggests the company may be facing challenges with its commercialization efforts or partnership agreements. As a clinical-stage biotech, this financial deterioration raises concerns about the company's ability to fund ongoing clinical trials and operations without additional capital raises, particularly given the declining cash position.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

ACLX's financial performance deteriorated meaningfully, with revenue declining substantially while operating losses expanded significantly year-over-year. The company's balance sheet contracted across key metrics, with cash and equivalents falling 24% to $80.3M and total assets declining 15% to $604.0M. While the company reduced total liabilities by 21%, the combination of lower revenue, higher losses, and declining cash reserves signals potential funding pressures ahead for this clinical-stage biotechnology company.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
-84%
-$137.6M-$253.1M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Capital Expenditure
Cash Flow
-82.7%
$13.4M$2.3M

Capex reduced 82.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Revenue
P&L
-79.4%
$107.9M$22.3M

Revenue declined 79.4% — significant demand weakness or market share loss warrants investigation.

Cash & Equivalents
Balance Sheet
-24.1%
$105.7M$80.3M

Cash decreased 24.1% — monitor burn rate and upcoming capital needs.

Current Assets
Balance Sheet
-22.9%
$599.3M$462.2M

Current assets declined 22.9% — monitor working capital adequacy and short-term liquidity.

Total Liabilities
Balance Sheet
-21.4%
$256.5M$201.6M

Liabilities reduced 21.4% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-16.9%
$125.4M$104.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Assets
Balance Sheet
-15.1%
$711.3M$604.0M

Total assets contracted 15.1% — asset sales, write-downs, or balance sheet optimization underway.

Stockholders Equity
Balance Sheet
-11.5%
$454.8M$402.4M

Equity decreased 11.5% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
Overview We are a clinical-stage biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases.
Although Chimeric Antigen Receptor T-cells (CAR-Ts) have shown benefits to date, they have primarily been constrained to existing biologic structures, which has limited their impact and opportunity.
Our novel synthetic binding scaffold, the D-Domain, is designed to overcome the limitations of traditional CAR-Ts.
Our lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel or anito-cel (formerly, CART-ddBCMA), which is currently being evaluated in our pivotal Phase 2 iMMagine-1, Phase 3 iMMagine-3, and Phase 2 GEM-AnitoFIRST trials in patients with multiple myeloma (MM).
In 2024, we completed dosing in our pivotal Phase 2 clinical trial (iMMagine-1) of anito-cel in patients with fourth line or later relapsed or refractory MM (rrMM).
+7 more — sign up free →
REMOVED
Overview We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
Although cell therapies have shown benefits to date, cell therapies have primarily been constrained to existing biologic structures, which has limited their impact and opportunity.
Our novel synthetic binding scaffold, the D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).
Our lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel or anito-cel (formerly, CART-ddBCMA), which is currently being evaluated in our pivotal Phase 2 iMMagine-1 and the Phase 3 iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM).
We received FDA clearance of an IND application and have initiated a Phase 1 trial in generalized myasthenia gravis (gMG) in 2024.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →